Extension Data Bolster Case Against Amyloid Therapy Coverage Restrictions
This industry-authored evidence review compiles long-term extension and safety data for donanemab and lecanemab to argue that Medicare's coverage restrictions should be reconsidered, informing pharmacists who counsel on anti-amyloid therapy and manage amyloid-related imaging abnormality (ARIA) risk.
📅 Journal publication: Aug 2026·Last updated: Aug 6, 2026
Amyloid therapies show promise in Alzheimer's treatment.
Understanding the long-term safety and efficacy of amyloid-targeting therapies is crucial for Alzheimer's treatment. Extension data show continued benefit with no new safety signals; gradual donanemab titration reduces ARIA risk. The study supports reconsideration of Medicare's coverage policy for amyloid-targeting therapies, but further real-world data may be needed. Amyloid-targeting therapies show sustained benefits and manageable safety profiles.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Boustani M, Klein EG, Zimmer JA, Wang H, Engle SE, Phipps A, Japha M, Schilling T, Hartry A, Alzheimer's Disease Neuroimaging Initiative
Citation:Boustani M, Klein EG, Zimmer JA, et al. Further data to address the Alzheimer's coverage with evidence development questions. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026;22(8):e71724. doi:10.1002/alz.71724